FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Susan Lerner

Research Profile

Disorders

B-Cell Chronic Lymphocytic Leukemia

Chemicals & Drugs

Concepts & Ideas

Procedures

Physiology

Disease Progression

Co-author Network

Publications

TOP 3
Carmen D Schweighofer; William G Wierda; Lynn L Barron; Kevin R Coombes; Bogdan A Czerniak; Alessandra Ferrajoli; Michael J Keating; Susan Lerner; Tadeusz Majewski; L Jeffrey Medeiros; Susan O'Brien; Rachel L Sargent; Lynne V Abruzzo
Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes.
Ravin Garg; Michael Keating; Susan Lerner; Lynne Abruzzo; Alessandra Ferrajoli; Sherry Pierce; William Wierda; Susan O'Brien
The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia.
Mariela Sivina; Elena Hartmann; Thomas J Kipps; Laura Rassenti; Diana Krupnik; Susan Lerner; Ruth Lapushin; Lianchun Xiao; Xuelin Huang; Lillian Werner; Donna Neuberg; Hagop Kantarjian; Susan O'Brien; William G Wierda; Michael J Keating; Andreas Rosenwald; Jan A Burger
CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Susan Lerner (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Carmen D Schweighofer; William G Wierda; Lynn L Barron; Kevin R Coombes; Bogdan A Czerniak; Alessandra Ferrajoli; Michael J Keating; Susan Lerner; Tadeusz Majewski; L Jeffrey Medeiros; Susan O'Brien; Rachel L Sargent; Lynne V Abruzzo
Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes.
The Journal of molecular diagnostics : JMD 2013;15(2):196-209.
2012: Ravin Garg; Michael Keating; Susan Lerner; Lynne Abruzzo; Alessandra Ferrajoli; Sherry Pierce; William Wierda; Susan O'Brien
The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia.
Cancer 2012;118(14):3531-7.
2011: Mariela Sivina; Elena Hartmann; Thomas J Kipps; Laura Rassenti; Diana Krupnik; Susan Lerner; Ruth Lapushin; Lianchun Xiao; Xuelin Huang; Lillian Werner; Donna Neuberg; Hagop Kantarjian; Susan O'Brien; William G Wierda; Michael J Keating; Andreas Rosenwald; Jan A Burger
CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia.
Blood 2011;117(5):1662-9.
2010: Simona Rossi; Masayoshi Shimizu; Elisa Barbarotto; Milena S Nicoloso; Federica Dimitri; Deepa Sampath; Muller Fabbri; Susan Lerner; Lynn L Barron; Laura Rassenti; Li Jiang; Lianchun Xiao; Jianhua Hu; Paola Secchiero; Giorgio Zauli; Stefano Volinia; Massimo Negrini; William G Wierda; Thomas J Kipps; William Plunkett; Kevin R Coombes; Lynne V Abruzzo; Michael J Keating; George A Calin
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival.
Blood 2010;116(6):945-52.
2010: Stefan Faderl; Alessandra Ferrajoli; William Wierda; Susan O'Brien; Susan Lerner; Michael J Keating
Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.
Cancer 2010;116(10):2360-5.
2010: Stefan Faderl; William Wierda; Susan O'Brien; Alessandra Ferrajoli; Susan Lerner; Michael J Keating
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.
Leukemia research 2010;34(3):284-8.
2010: Gheath Alatrash; Maher Albitar; Susan O'Brien; Xuemei Wang; Taghi Manshouri; Stefan Faderl; Alessandra Ferrajoli; Jan Burger; Guillermo Garcia-Manero; Hagop M Kantarjian; Susan Lerner; Michael J Keating; Jan A Burger
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).
British journal of haematology 2010;148(3):386-93.
2009: Nitin Jain; William G Wierda; Alessandra Ferrajoli; Franklin Wong; Susan Lerner; Michael Keating; Susan O'Brien
A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia.
Cancer 2009;115(19):4533-9.
2009: Katherine I Lin; Constantine S Tam; Michael J Keating; William G Wierda; Susan O'Brien; Susan Lerner; Kevin R Coombes; Ellen Schlette; Alessandra Ferrajoli; Lynn L Barron; Thomas Kipps; Laura Rassenti; Stefan Faderl; Andrew Lamb; Lynne V Abruzzo
Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.
Blood 2009;113(14):3168-71.
2009: Jan A Burger; Susan O'Brien; Xuemei Wang; Stefan Faderl; Alessandra Ferrajoli; Kim-Anh Do; Guillermo Garcia-Manero; Jorge Cortes; Deborah Thomas; Charles Koller; Jan Burger; Susan Lerner; Andrew Lamb; Michael Keating
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(10):1637-43.
2009: Apostolia-Maria Tsimberidou; Sijin Wen; Peter McLaughlin; Susan O'Brien; William G Wierda; Susan Lerner; Sara Strom; Emil J Freireich; L Jeffrey Medeiros; Hagop M Kantarjian; Michael J Keating
Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(6):904-10.
2009: Apostolia-Maria Tsimberidou; Constantine Tam; Lynne V Abruzzo; Susan O'Brien; William G Wierda; Susan Lerner; Hagop M Kantarjian; Michael J Keating
Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia.
Cancer 2009;115(2):373-80.
2008: Constantine S Tam; Susan O'Brien; William G Wierda; Andrew Lamb; Sijin Wen; Kim-Anh Do; Deborah A Thomas; Jorge Cortes; Susan Lerner; Michael J Keating
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
Blood 2008;112(4):975-80.
2008: Constantine S Tam; Joselle Otero-Palacios; Lynne V Abruzzo; Jeffrey L Jorgensen; Alessandra Ferrajoli; William G Wierda; Susan Lerner; Susan O'Brien; Michael J Keating
Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients.
British journal of haematology 2008;141(1):36-40.
2008: Varsha Gandhi; Constantine Tam; Susan O'Brien; Roxanne C Jewell; Carlos O Rodriguez; Susan Lerner; William Plunkett; Michael J Keating
Phase I trial of nelarabine in indolent leukemias.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(7):1098-105.
2008: Apostolia-Maria Tsimberidou; William G Wierda; William Plunkett; Razelle Kurzrock; Susan O'Brien; Sijin Wen; Alessandra Ferrajoli; Farhad Ravandi-Kashani; Guillermo Garcia-Manero; Zeev Estrov; Thomas Kipps; Jennifer R Brown; Albert Fiorentino; Susan Lerner; Hagop M Kantarjian; Michael J Keating
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):196-203.
2007: Apostolia-Maria Tsimberidou; Sijin Wen; Susan O'Brien; Peter McLaughlin; William G Wierda; Alessandra Ferrajoli; Stefan Faderl; John Manning; Susan Lerner; Chinh V Mai; Alma M Rodriguez; Mark Hess; Kim-Anh Do; Emil J Freireich; Hagop M Kantarjian; L Jeffrey Medeiros; Michael J Keating
Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(29):4648-56.
2007: Constantine S Tam; Susan O'Brien; Susan Lerner; Issa Khouri; Alessandra Ferrajoli; Stefan Faderl; Mary L Browning; Apostolia-Maria Tsimberidou; Andrew Lamb; William G Wierda
The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.
Leukemia & lymphoma 2007;48(10):1931-9.
2007: William G Wierda; Susan O'Brien; Xuemei Wang; Stefan Faderl; Alessandra Ferrajoli; Kim-Anh Do; Jorge Cortes; Deborah Thomas; Guillermo Garcia-Manero; Charles Koller; Miloslav Beran; Francis Giles; Farhad Ravandi; Susan Lerner; Andrew Lamb; Michael Keating
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.
Blood 2007;109(11):4679-85.
2007: Gautam Borthakur; Susan O'Brien; William G Wierda; Deborah A Thomas; Jorge E Cortes; Francis Giles; Hagop M Kantarjian; Susan Lerner; Michael J Keating
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
British journal of haematology 2007;136(6):800-5.
2006: Apostolia-Maria Tsimberidou; Susan O'Brien; Hagop M Kantarjian; Charles Koller; Fredrick B Hagemeister; Luis Fayad; Susan Lerner; Carlos E Bueso-Ramos; Michael J Keating
Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience.
Cancer 2006;107(6):1294-302.
2006: Varsha Gandhi; William Plunkett; Peter L Bonate; Min Du; Billie Nowak; Susan Lerner; Michael J Keating
Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(13):4011-7.
2006: Apostolia-Maria Tsimberidou; Daniel Catovsky; Ellen Schlette; Susan O'Brien; William G Wierda; Andrew Lamb; Guillermo Garcia-Manero; Sijin Wen; Kim-Anh Do; Susan Lerner; Michael J Keating
Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.
Cancer 2006;107(1):125-35.
2006: Apostolia-Maria Tsimberidou; Susan O'Brien; Issa Khouri; Francis Giles; Hagop M Kantarjian; Richard Champlin; Sijin Wen; Kim-Anh Do; Susan C Smith; Susan Lerner; Emil J Freireich; Michael J Keating
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(15):2343-51.
2006: Xifeng Wu; Jian Gu; H Barton Grossman; Christopher I Amos; Carol J Etzel; Maosheng Huang; Qing Zhang; Randall E Millikan; Susan Lerner; Colin P N Dinney; Margaret R Spitz
Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes.
American journal of human genetics 2006;78(3):464-79.
2006: William G Wierda; Susan O'Brien; Stefan Faderl; Alessandra Ferrajoli; Xuemei Wang; Kim-Anh Do; Guillermo Garcia-Manero; Deborah Thomas; Jorge Cortes; Farhad Ravandi-Kashani; Francis Giles; Susan Lerner; Andrew Lamb; Michael Keating
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.
Cancer 2006;106(2):337-45.
2005: Farhad Ravandi; Susan O'Brien; Dan Jones; Susan Lerner; Stefan Faderl; Alessandra Ferrajoli; William G Wierda; Guillermo Garcia-Manero; Deborah Thomas; Charles Koller; Srdan Verstovsek; Francis Giles; Jorge Cortes; Marco Herling; Andrew Lamb; Michael Keating
T-cell prolymphocytic leukemia: a single-institution experience.
Clinical lymphoma & myeloma 2005;6(3):234-9.
2005: M Motta; Laura Rassenti; B J Shelvin; Susan Lerner; Thomas Kipps; M J Keating; William G Wierda
Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia.
Leukemia 2005;19(10):1788-93.
2005: Dan Leibovici; H Barton Grossman; Colin P N Dinney; Randall E Millikan; Susan Lerner; Yunfei Wang; Jian Gu; Qiong Dong; Xifeng Wu
Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(24):5746-56.
2005: Michael J Keating; Susan O'Brien; Maher Albitar; Susan Lerner; William Plunkett; Francis Giles; Michael Andreeff; Jorge Cortes; Stefan Faderl; Deborah Thomas; Charles Koller; William G Wierda; Michelle A Detry; Alice Lynn; Andrew Lamb
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4079-88.
2005: William G Wierda; Susan O'Brien; Sijin Wen; Stefan Faderl; Guillermo Garcia-Manero; Deborah Thomas; Kim-Anh Do; Jorge Cortes; Charles Koller; Miloslav Beran; Alessandra Ferrajoli; Francis Giles; Susan Lerner; Maher Albitar; Andrew Lamb; Michael Keating
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4070-8.
2004: Apostolia-Maria Tsimberidou; Michael J Keating; Francis Giles; William G Wierda; Alessandra Ferrajoli; Susan Lerner; Miloslav Beran; Michael Andreeff; Hagop M Kantarjian; Susan O'Brien
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Cancer 2004;100(12):2583-91.
2003: Susan M O'Brien; Hagop M Kantarjian; Deborah A Thomas; Jorge Cortes; Francis Giles; William G Wierda; Charles Koller; Alessandra Ferrajoli; Mary L Browning; Susan Lerner; Maher Albitar; Michael J Keating
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
Cancer 2003;98(12):2657-63.
2003: Alessandra Ferrajoli; Susan M O'Brien; Jorge E Cortes; Francis Giles; Deborah A Thomas; Stefan Faderl; Razelle Kurzrock; Susan Lerner; Dimitrios P Kontoyiannis; Michael J Keating
Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
Cancer 2003;98(4):773-8.
2003: William G Wierda; Marcella M Johnson; Kim-Anh Do; Taghi Manshouri; Amanda Dey; Susan O'Brien; Francis Giles; Andrew Lamb; Deborah Thomas; Stefan Faderl; Susan Lerner; Michael Keating; Maher Albitar
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia.
British journal of haematology 2003;120(3):452-6.
2002: Michael J Keating; Susan O'Brien; Dimitrios P Kontoyiannis; William Plunkett; Charles Koller; Miloslav Beran; Susan Lerner; Andrew Lamb
Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia.
Leukemia & lymphoma 2002;43(9):1755-62.
2002: Alessandra Ferrajoli; Michael J Keating; Taghi Manshouri; Francis Giles; Amanda Dey; Zeev Estrov; Charles Koller; Razelle Kurzrock; Deborah A Thomas; Stefan Faderl; Susan Lerner; Susan O'Brien; Maher Albitar
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia.
Blood 2002;100(4):1215-9.
2002: R Oudat; Michael J Keating; Susan Lerner; Susan O'Brien; Maher Albitar
Significance of the levels of bone marrow lymphoid infiltrate in chronic lymphocytic leukemia patients with nodular partial remission.
Leukemia 2002;16(4):632-5.
2001: Yang O Huh; Michael J Keating; Helene Saffer; Iman Jilani; Susan Lerner; Maher Albitar
Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia.
American journal of clinical pathology 2001;116(3):437-43.
2001: S Ibrahim; Michael Keating; Kim-Anh Do; Susan O'Brien; Yang O Huh; Iman Jilani; Susan Lerner; Hagop M Kantarjian; Maher Albitar
CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia.
Blood 2001;98(1):181-6.
2001: Susan M O'Brien; Andrew Lamb; Deborah A Thomas; Francis Giles; Emil J Freireich; Jorge Cortes; Susan Lerner; Michael J Keating
Rituximab dose-escalation trial in chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(8):2165-70.
2001: Alessandra Ferrajoli; Taghi Manshouri; Zeev Estrov; Michael J Keating; Susan O'Brien; Susan Lerner; Miloslav Beran; Hagop M Kantarjian; Emil J Freireich; Maher Albitar
High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(4):795-9.
2001: Susan M O'Brien; Hagop M Kantarjian; Jorge Cortes; Miloslav Beran; Charles Koller; Francis Giles; Susan Lerner; Michael Keating
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1414-20.
2001: Luis Fayad; Michael J Keating; James M Reuben; Susan O'Brien; Bang-Ning Lee; Susan Lerner; Razelle Kurzrock
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome.
Blood 2001;97(1):256-63.
2000: Farhad Ravandi-Kashani; Susan O'Brien; Taghi Manshouri; Susan Lerner; S Sim; K Dodd; Andrew Lamb; Emil J Freireich; Michael Keating; Maher Albitar
Variations in the low levels of cyclin D1/BCL1 have prognostic value in chronic lymphocytic leukemia.
Leukemia research 2000;24(6):469-74.
2000: Michael J Keating; Terry L Smith; Susan Lerner; Susan O'Brien; LE Robertson; Andrew Lamb; Emil J Freireich
Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia.
Leukemia & lymphoma 2000;37(1-2):71-85.
1998: P Starostik; Taghi Manshouri; Susan O'Brien; Emil J Freireich; Andrew Lamb; Mohammad A Haidar; Susan Lerner; Michael Keating; Maher Albitar
Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia.
Cancer research 1998;58(20):4552-7.
1998: E J Anaissie; Dimitrios P Kontoyiannis; Susan O'Brien; Andrew Lamb; L Robertson; Susan Lerner; Michael J Keating
Infections in patients with chronic lymphocytic leukemia treated with fludarabine.
Annals of internal medicine 1998;129(7):559-66.
1998: Michael J Keating; Susan O'Brien; Susan Lerner; Charles Koller; Miloslav Beran; LE Robertson; Emil J Freireich; Elihu Estey; Andrew Lamb
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
Blood 1998;92(4):1165-71.
1998: M de Lima; Susan O'Brien; Susan Lerner; Michael J Keating
Chronic lymphocytic leukemia in the young patient.
Seminars in oncology 1998;25(1):107-16.
1997: Susan O'Brien; Andrew Lamb; Miloslav Beran; Charles Koller; Moshe Talpaz; Susan Lerner; Michael J Keating
Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia.
Leukemia 1997;11(10):1631-5.
1997: James C Cusack; John F Seymour; Susan Lerner; Michael J Keating; Raphael E Pollock
Role of splenectomy in chronic lymphocytic leukemia.
Journal of the American College of Surgeons 1997;185(3):237-43.
1997: Issa F Khouri; Donna Przepiorka; Koen van Besien; Susan O'Brien; J Lynn Palmer; Susan Lerner; RC Mehra; huib vriesendorp; Borje S Andersson; Sergio Giralt; Martin Körbling; Michael J Keating; Richard E Champlin
Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease.
British journal of haematology 1997;97(2):466-73.
1996: Michael J Keating; Susan O'Brien; Peter McLaughlin; Meletios A Dimopoulos; Varsha Gandhi; William Plunkett; Susan Lerner; Andrew Lamb; Elihu Estey
Clinical experience with fludarabine in hemato-oncology.
Hematology and cell therapy 1996;38 Suppl 2():S83-91.
1995: LE Robertson; Susan O'Brien; Andrew Lamb; Charles Koller; Miloslav Beran; Michael Andreeff; Susan Lerner; William Plunkett; Michael J Keating
A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.
Leukemia 1995;9(9):1444-9.
1995: Susan O'Brien; Andrew Lamb; Miloslav Beran; LE Robertson; Charles Koller; Susan Lerner; Michael J Keating
Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy.
Blood 1995;86(4):1298-300.
1995: J F Seymour; LE Robertson; Susan O'Brien; Susan Lerner; Michael J Keating
Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies.
Leukemia & lymphoma 1995;18(5-6):493-6.
1995: LE Robertson; Susan O'Brien; Andrew Lamb; Charles Koller; Miloslav Beran; Michael Andreeff; Susan Lerner; Michael J Keating
Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia.
Leukemia 1995;9(6):943-5.
1993: Susan O'Brien; Andrew Lamb; Miloslav Beran; T Smith; Charles Koller; Elihu Estey; LE Robertson; Susan Lerner; Michael Keating
Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.
Blood 1993;82(6):1695-700.
1993: A Kemena; Susan O'Brien; Andrew Lamb; L Robertson; Charles Koller; Miloslav Beran; Elihu Estey; William Plunkett; Susan Lerner; Michael J Keating
Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule.
Leukemia & lymphoma 1993;10(3):187-93.
1993: Michael J Keating; R Holmes; Susan Lerner; Dah H Ho
L-asparaginase and PEG asparaginase--past, present, and future.
Leukemia & lymphoma 1993;10 Suppl():153-7.